Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC gynecological cancer cooperative group study

J. V. T. H. Hamerlynck; A. P. Maskens; C. Mangioni; M. E. L. van der Burg; J. A. M. J. Wils; J. B. Vermorken; N. Rotmensz

doi:10.1016/0090-8258(85)90045-9

Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC gynecological cancer cooperative group study

J. V. T. H. Hamerlynck^*
, A. P. Maskens
, C. Mangioni
, M. E. L. van der Burg
, J. A. M. J. Wils
, J. B. Vermorken
, N. Rotmensz

^*Corresponding author for this work

Amsterdam UMC - University of Amsterdam

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Progestin therapy of ovarian carcinoma in the past has been reported to lead to varying response rates. A multicenter phase II study of high-dose MPA was conducted in 53 patients with epithelial ovarian cancer who had received adequate trials of conventional therapy with cytotoxic agents. Forty-one patients were included for response and toxicity evaluations. Only one partial response has been recorded with a duration of 20 weeks. Stabilization of disease was observed in 7 patients. The present investigation shows that MPA given at the present high dose is not effective in patients extensively pretreated with chemotherapy. © 1985.

Original language	English
Pages (from-to)	313-316
Journal	Gynecologic oncology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/0090-8258(85)90045-9
Publication status	Published - 1985
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/0090-8258(85)90045-9

Cite this

@article{df0e204a43e7457fac3e4d7e6f6dfa49,

title = "Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC gynecological cancer cooperative group study",

abstract = "Progestin therapy of ovarian carcinoma in the past has been reported to lead to varying response rates. A multicenter phase II study of high-dose MPA was conducted in 53 patients with epithelial ovarian cancer who had received adequate trials of conventional therapy with cytotoxic agents. Forty-one patients were included for response and toxicity evaluations. Only one partial response has been recorded with a duration of 20 weeks. Stabilization of disease was observed in 7 patients. The present investigation shows that MPA given at the present high dose is not effective in patients extensively pretreated with chemotherapy. {\textcopyright} 1985.",

author = "Hamerlynck, \{J. V. T. H.\} and Maskens, \{A. P.\} and C. Mangioni and \{van der Burg\}, \{M. E. L.\} and Wils, \{J. A. M. J.\} and Vermorken, \{J. B.\} and N. Rotmensz",

year = "1985",

doi = "10.1016/0090-8258(85)90045-9",

language = "English",

volume = "22",

pages = "313--316",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer

T2 - An EORTC gynecological cancer cooperative group study

AU - Hamerlynck, J. V. T. H.

AU - Maskens, A. P.

AU - Mangioni, C.

AU - van der Burg, M. E. L.

AU - Wils, J. A. M. J.

AU - Vermorken, J. B.

AU - Rotmensz, N.

PY - 1985

Y1 - 1985

N2 - Progestin therapy of ovarian carcinoma in the past has been reported to lead to varying response rates. A multicenter phase II study of high-dose MPA was conducted in 53 patients with epithelial ovarian cancer who had received adequate trials of conventional therapy with cytotoxic agents. Forty-one patients were included for response and toxicity evaluations. Only one partial response has been recorded with a duration of 20 weeks. Stabilization of disease was observed in 7 patients. The present investigation shows that MPA given at the present high dose is not effective in patients extensively pretreated with chemotherapy. © 1985.

AB - Progestin therapy of ovarian carcinoma in the past has been reported to lead to varying response rates. A multicenter phase II study of high-dose MPA was conducted in 53 patients with epithelial ovarian cancer who had received adequate trials of conventional therapy with cytotoxic agents. Forty-one patients were included for response and toxicity evaluations. Only one partial response has been recorded with a duration of 20 weeks. Stabilization of disease was observed in 7 patients. The present investigation shows that MPA given at the present high dose is not effective in patients extensively pretreated with chemotherapy. © 1985.

UR - https://www.scopus.com/pages/publications/0022398461

UR - https://www.ncbi.nlm.nih.gov/pubmed/2998957

U2 - 10.1016/0090-8258(85)90045-9

DO - 10.1016/0090-8258(85)90045-9

M3 - Article

C2 - 2998957

SN - 0090-8258

VL - 22

SP - 313

EP - 316

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 3

ER -

Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC gynecological cancer cooperative group study

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this